clorazepate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
diazepam derivatives	711	57109-90-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: clorazepate monopotassium clorazepate potassium clorazepic acid clorazepate chlorazepate clorazepate dipotassium dipotassium clorazepate potassium clorazepate	A water-soluble benzodiazepine derivative effective in the treatment of anxiety. It has also muscle relaxant and anticonvulsant actions. Molecular weight: 314.73 Formula: C16H11ClN2O3 CLOGP: 2.51 LIPINSKI: 0 HAC: 5 HDO: 2 TPSA: 78.76 ALOGS: -4.10 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

clorazepate monopotassium
clorazepate potassium
clorazepic acid
clorazepate
chlorazepate
clorazepate dipotassium
dipotassium clorazepate
potassium clorazepate

A water-soluble benzodiazepine derivative effective in the treatment of anxiety. It has also muscle relaxant and anticonvulsant actions.

Molecular weight: 314.73
Formula: C16H11ClN2O3
CLOGP: 2.51
LIPINSKI: 0
HAC: 5
HDO: 2
TPSA: 78.76
ALOGS: -4.10
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
20	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	5.45 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	91 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.40 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
June 23, 1972	FDA	RECORDATI RARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coma	219.83	17.39	133	8923	56746	50539322
Coma blister	105.11	17.39	19	9037	136	50595932
Suicide attempt	99.90	17.39	79	8977	51653	50544415
Somnolence	81.05	17.39	118	8938	154867	50441201
Seizure	66.36	17.39	93	8963	117781	50478287
Disorientation	65.93	17.39	53	9003	35431	50560637
Toxic epidermal necrolysis	65.66	17.39	43	9013	20949	50575119
Neurological decompensation	62.28	17.39	21	9035	2249	50593819
Erythrodermic psoriasis	57.39	17.39	16	9040	905	50595163
Overdose	56.58	17.39	79	8977	99648	50496420
Drug abuse	55.97	17.39	61	8995	59785	50536283
Tissue infiltration	55.44	17.39	14	9042	539	50595529
Dermatitis exfoliative	55.22	17.39	24	9032	5118	50590950
Basal ganglion degeneration	54.45	17.39	13	9043	395	50595673
Drug interaction	54.35	17.39	114	8942	199507	50396561
Antithrombin III	54.03	17.39	11	9045	156	50595912
Behaviour disorder	53.61	17.39	19	9037	2361	50593707
Fall	51.75	17.39	154	8902	334778	50261290
Rhabdomyolysis	51.60	17.39	48	9008	38979	50557089
Uterine enlargement	46.34	17.39	14	9042	1052	50595016
Stupor	46.05	17.39	19	9037	3564	50592504
Hyperthyroidism	45.71	17.39	28	9028	12147	50583921
Electrolyte imbalance	43.77	17.39	31	9025	17138	50578930
Monoplegia	43.53	17.39	17	9039	2766	50593302
Euphoric mood	40.54	17.39	18	9038	4037	50592031
Anaesthesia	40.52	17.39	10	9046	350	50595718
Inguinal hernia	39.87	17.39	14	9042	1692	50594376
Multiple organ dysfunction syndrome	39.73	17.39	47	9009	50290	50545778
Loss of consciousness	38.69	17.39	68	8988	104285	50491783
Psychogenic seizure	37.02	17.39	13	9043	1572	50594496
Toxicity to various agents	34.93	17.39	100	8956	212399	50383669
Poisoning deliberate	34.40	17.39	20	9036	7892	50588176
Psychomotor hyperactivity	33.92	17.39	21	9035	9280	50586788
Cholecystitis	32.96	17.39	24	9032	13847	50582221
Drug monitoring procedure incorrectly performed	32.61	17.39	7	9049	130	50595938
Sudden cardiac death	30.68	17.39	12	9044	1960	50594108
Intentional overdose	30.30	17.39	46	9010	62458	50533610
Dysaesthesia	29.27	17.39	14	9042	3721	50592347
Drug ineffective	29.12	17.39	65	8991	819268	49776800
Granulomatous liver disease	29.07	17.39	9	9047	734	50595334
Hypochromic anaemia	28.80	17.39	11	9045	1685	50594383
Eosinophilia	28.70	17.39	25	9031	18627	50577441
Klebsiella infection	28.17	17.39	17	9039	7177	50588891
Neuroleptic malignant syndrome	28.14	17.39	20	9036	11110	50584958
Joint swelling	28.12	17.39	5	9051	245281	50350787
Anterograde amnesia	28.01	17.39	8	9048	494	50595574
Respiratory disorder	27.77	17.39	31	9025	31156	50564912
Social avoidant behaviour	26.63	17.39	12	9044	2785	50593283
Derailment	25.90	17.39	5	9051	53	50596015
Serotonin syndrome	24.50	17.39	26	9030	24687	50571381
Intervertebral disc disorder	24.36	17.39	13	9043	4347	50591721
Rash	23.78	17.39	26	9030	437445	50158623
Depressed level of consciousness	23.44	17.39	37	9019	51916	50544152
Lung disorder	23.18	17.39	34	9022	44765	50551303
Livedo reticularis	22.87	17.39	10	9046	2162	50593906
Tremor	22.79	17.39	58	8998	114845	50481223
Somatic delusion	22.75	17.39	7	9049	559	50595509
Hyperpyrexia	22.59	17.39	11	9045	3038	50593030
Conversion disorder	22.34	17.39	9	9047	1587	50594481
Mydriasis	22.15	17.39	17	9039	10610	50585458
Abdominal discomfort	22.07	17.39	7	9049	231634	50364434
Hyperventilation	21.74	17.39	13	9043	5396	50590672
Cutaneous vasculitis	21.58	17.39	12	9044	4350	50591718
Neonatal aspiration	21.03	17.39	5	9051	149	50595919
Cyanosis	20.68	17.39	19	9037	15165	50580903
Abdominal tenderness	20.56	17.39	14	9042	7266	50588802
Pain	19.63	17.39	47	9009	578856	50017212
Colitis ischaemic	19.39	17.39	15	9041	9468	50586600
Confusional state	19.33	17.39	75	8981	185853	50410215
Intra-abdominal haematoma	19.14	17.39	8	9048	1549	50594519
Drug withdrawal syndrome	19.09	17.39	23	9033	25058	50571010
Dysarthria	18.79	17.39	28	9028	37375	50558693
Transaminases increased	18.75	17.39	24	9032	27800	50568268
Hyponatraemia	18.51	17.39	48	9008	96091	50499977
Sedation	18.45	17.39	25	9031	30585	50565483
Renal cyst	18.33	17.39	14	9042	8673	50587395
Urinary retention	18.29	17.39	23	9033	26167	50569901
Nasopharyngitis	18.07	17.39	6	9050	192921	50403147
Hyperthermia	17.57	17.39	13	9043	7683	50588385
Swelling	17.54	17.39	7	9049	200865	50395203
Shock	17.48	17.39	20	9036	20630	50575438

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coma	151.39	19.41	89	4767	39361	29530310
Hepatitis acute	74.77	19.41	31	4825	6431	29563240
Anticoagulation drug level above therapeutic	47.92	19.41	16	4840	1815	29567856
Wrong patient	45.57	19.41	9	4847	119	29569552
Somnolence	44.17	19.41	65	4791	93890	29475781
Wrong patient received product	40.74	19.41	15	4841	2267	29567404
Acute respiratory distress syndrome	36.09	19.41	30	4826	22905	29546766
Aggression	35.43	19.41	36	4820	35505	29534166
Cor pulmonale acute	34.75	19.41	8	4848	226	29569445
Prothrombin level decreased	30.71	19.41	10	4846	1048	29568623
Faecal vomiting	30.53	19.41	8	4848	390	29569281
Asphyxia	28.56	19.41	15	4841	5300	29564371
Sedation	27.87	19.41	23	4833	17382	29552289
Pneumonia aspiration	27.50	19.41	32	4824	36705	29532966
Toxic skin eruption	27.17	19.41	18	4838	9739	29559932
Dermatitis bullous	27.07	19.41	15	4841	5891	29563780
Overdose	26.25	19.41	47	4809	79772	29489899
Clonus	26.12	19.41	11	4845	2367	29567304
Lung disorder	25.36	19.41	28	4828	30334	29539337
Tachycardia	24.27	19.41	43	4813	72367	29497304
Rhabdomyolysis	24.21	19.41	39	4817	60769	29508902
Abnormal behaviour	24.09	19.41	24	4832	23103	29546568
Dyspnoea	23.86	19.41	12	4844	326720	29242951
Hypothermia	23.23	19.41	16	4840	9223	29560448
Eosinophilia	23.09	19.41	23	4833	22138	29547533
Cardio-respiratory arrest	22.29	19.41	34	4822	50567	29519104
Disturbance in attention	21.88	19.41	22	4834	21402	29548269
Pancreatitis acute	21.25	19.41	23	4833	24362	29545309
Cytotoxic oedema	20.94	19.41	5	4851	166	29569505
Intentional product misuse	20.78	19.41	27	4829	34634	29535037
Electromyogram abnormal	19.97	19.41	4	4852	57	29569614
Rash maculo-papular	19.59	19.41	22	4834	24267	29545404

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coma	352.43	16.30	213	11782	87402	64399335
Somnolence	117.87	16.30	166	11829	203479	64283258
Suicide attempt	100.05	16.30	92	11903	70915	64415822
Coma blister	96.40	16.30	19	11976	217	64486520
Toxic epidermal necrolysis	74.54	16.30	59	11936	37107	64449630
Overdose	69.41	16.30	114	11881	159452	64327285
Disorientation	68.44	16.30	67	11928	55761	64430976
Hepatitis acute	62.70	16.30	36	11959	13353	64473384
Rhabdomyolysis	57.78	16.30	78	11917	91648	64395089
Neurological decompensation	54.39	16.30	23	11972	4413	64482324
Drug interaction	52.44	16.30	167	11828	361916	64124821
Stupor	50.65	16.30	24	11971	6011	64480726
Erythrodermic psoriasis	48.27	16.30	16	11979	1563	64485174
Seizure	47.06	16.30	99	11896	166793	64319944
Poisoning deliberate	47.05	16.30	30	11965	13428	64473309
Tissue infiltration	44.39	16.30	12	11983	581	64486156
Basal ganglion degeneration	43.82	16.30	11	11984	397	64486340
Dermatitis exfoliative	43.63	16.30	26	11969	10326	64476411
Eosinophilia	43.52	16.30	44	11951	38032	64448705
Aggression	43.21	16.30	48	11947	46184	64440553
Lung disorder	41.89	16.30	54	11941	60646	64426091
Behaviour disorder	41.33	16.30	19	11976	4443	64482294
Uterine enlargement	41.12	16.30	12	11983	769	64485968
Drug abuse	40.22	16.30	81	11914	132293	64354444
Intentional overdose	40.05	16.30	65	11930	89879	64396858
Faecal vomiting	37.91	16.30	12	11983	1013	64485724
Fall	37.49	16.30	165	11830	416661	64070076
Hyperthyroidism	36.74	16.30	29	11966	18150	64468587
Monoplegia	36.15	16.30	16	11979	3427	64483310
Sedation	35.27	16.30	41	11954	41421	64445316
Colitis ischaemic	35.13	16.30	25	11970	13389	64473348
Toxicity to various agents	35.05	16.30	147	11848	363366	64123371
Anticoagulation drug level above therapeutic	34.73	16.30	15	11980	3030	64483707
Neuroleptic malignant syndrome	34.41	16.30	32	11963	24964	64461773
Euphoric mood	34.32	16.30	19	11976	6572	64480165
Anaesthesia	33.83	16.30	9	11986	410	64486327
Prothrombin level decreased	33.53	16.30	12	11983	1474	64485263
Pneumonia aspiration	32.24	16.30	47	11948	59224	64427513
Urinary retention	31.20	16.30	42	11953	49159	64437578
Psychogenic seizure	31.03	16.30	12	11983	1829	64484908
Disturbance in attention	30.64	16.30	38	11957	41036	64445701
Anterograde amnesia	30.05	16.30	9	11986	631	64486106
Wrong patient	29.91	16.30	7	11988	187	64486550
Joint swelling	29.34	16.30	3	11992	215379	64271358
Antithrombin III	29.11	16.30	6	11989	87	64486650
Psychomotor hyperactivity	29.08	16.30	23	11972	14428	64472309
Sudden cardiac death	28.87	16.30	15	11980	4572	64482165
Wrong patient received product	28.66	16.30	14	11981	3748	64482989
Depressed level of consciousness	28.59	16.30	53	11942	81383	64405354
Psychomotor skills impaired	28.37	16.30	14	11981	3831	64482906
Electrolyte imbalance	26.72	16.30	28	11967	25215	64461522
Drug withdrawal syndrome	26.70	16.30	31	11964	31260	64455477
Wrong product administered	26.46	16.30	17	11978	7703	64479034
Respiratory disorder	26.28	16.30	33	11962	36078	64450659
Cardio-respiratory arrest	26.13	16.30	57	11938	98336	64388401
Multiple organ dysfunction syndrome	26.08	16.30	58	11937	101355	64385382
Cor pulmonale acute	26.01	16.30	8	11987	614	64486123
Drug dependence	25.14	16.30	31	11964	33281	64453456
Drug monitoring procedure incorrectly performed	24.85	16.30	7	11988	395	64486342
Shock	24.79	16.30	33	11962	38207	64448530
Derailment	24.36	16.30	5	11990	71	64486666
Miosis	24.33	16.30	20	11975	13246	64473491
Irritability	24.26	16.30	32	11963	36714	64450023
Fatigue	24.20	16.30	66	11929	748664	63738073
Intervertebral disc disorder	23.62	16.30	13	11982	4444	64482293
Social avoidant behaviour	23.35	16.30	13	11982	4544	64482193
Livedo reticularis	23.01	16.30	12	11983	3685	64483052
Cholecystitis	22.99	16.30	23	11972	19613	64467124
Hyponatraemia	22.84	16.30	70	11925	148269	64338468
Hypothermia	22.78	16.30	23	11972	19833	64466904
Serotonin syndrome	22.60	16.30	32	11963	39250	64447487
Loss of consciousness	21.91	16.30	69	11926	148296	64338441
Conversion disorder	21.36	16.30	9	11986	1710	64485027
Somatic delusion	21.12	16.30	7	11988	683	64486054
Electromyogram abnormal	21.04	16.30	5	11990	143	64486594
Rash maculo-papular	20.94	16.30	34	11961	46992	64439745
Inguinal hernia	20.90	16.30	13	11982	5568	64481169
Granulomatous liver disease	20.72	16.30	8	11987	1214	64485523
Pancreatitis acute	20.48	16.30	32	11963	42823	64443914
Mydriasis	19.92	16.30	19	11976	15293	64471444
Tachycardia	19.78	16.30	67	11928	149512	64337225
Dermatitis bullous	19.69	16.30	17	11978	12037	64474700
Dysaesthesia	19.64	16.30	12	11983	4983	64481754
Withdrawal syndrome	19.59	16.30	23	11972	23469	64463268
Hepatocellular injury	19.19	16.30	32	11963	45203	64441534
Lipase increased	18.98	16.30	18	11977	14384	64472353
Asphyxia	18.77	16.30	15	11980	9551	64477186
Hypochromic anaemia	18.60	16.30	9	11986	2359	64484378
Arthralgia	18.31	16.30	34	11961	442226	64044511
Toxic skin eruption	17.97	16.30	20	11975	19264	64467473
Pain	17.69	16.30	49	11946	553462	63933275
Dysarthria	17.60	16.30	36	11959	59370	64427367
Lymphocytosis	17.60	16.30	10	11985	3634	64483103
Bradycardia	17.46	16.30	55	11940	118164	64368573
Abnormal behaviour	17.32	16.30	26	11969	33596	64453141
Sudden death	17.30	16.30	20	11975	20076	64466661
Cutaneous vasculitis	16.80	16.30	12	11983	6461	64480276
Peripheral swelling	16.76	16.30	9	11986	209144	64277593
Confusional state	16.73	16.30	94	11901	261050	64225687
Klebsiella infection	16.37	16.30	16	11979	13265	64473472
Nasopharyngitis	16.36	16.30	8	11987	196065	64290672

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05BA05	NERVOUS SYSTEM PSYCHOLEPTICS ANXIOLYTICS Benzodiazepine derivatives
FDA CS	M0002356	Benzodiazepines
CHEBI has role	CHEBI:35474	anti-anxiety agents
CHEBI has role	CHEBI:35623	anticonvulsants
CHEBI has role	CHEBI:50266	Prodrugs
CHEBI has role	CHEBI:50268	GABA modulators
MeSH PA	D014151	Anti-Anxiety Agents
MeSH PA	D000927	Anticonvulsants
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D018682	GABA Agents
MeSH PA	D018757	GABA Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
FDA EPC	N0000175694	Benzodiazepine

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Anxiety	indication	48694002
Alcohol withdrawal syndrome	indication	191480000
Partial Epilepsy Treatment Adjunct	indication
Suicidal thoughts	contraindication	6471006
Alcohol intoxication	contraindication	25702006
Depressive disorder	contraindication	35489007
Substance abuse	contraindication	66214007
Psychotic disorder	contraindication	69322001
Sleep apnea	contraindication	73430006	DOID:0050847
Kidney disease	contraindication	90708001	DOID:557
Hypoalbuminemia	contraindication	119247004
Disease of liver	contraindication	235856003	DOID:409
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Severe chronic obstructive pulmonary disease	contraindication	313299006
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Central nervous system depression	contraindication	418072004

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.55	acidic
pKa2	13.86	acidic
pKa3	2.31	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
GABA-A receptor alpha-1/beta-2/gamma-2	Ion channel	P14867 P18507 P47870	GBRA1_HUMAN GBRG2_HUMAN GBRB2_HUMAN	POSITIVE ALLOSTERIC MODULATOR	EC50	7.47	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-2/beta-3/gamma-2	Ion channel	P18507 P28472 P47869	GBRG2_HUMAN GBRB3_HUMAN GBRA2_HUMAN	POSITIVE ALLOSTERIC MODULATOR			WOMBAT-PK	CHEMBL
GABA-A receptor alpha-3/beta-3/gamma-2	Ion channel	P18507 P28472 P34903	GBRG2_HUMAN GBRB3_HUMAN GBRA3_HUMAN	POSITIVE ALLOSTERIC MODULATOR			WOMBAT-PK	CHEMBL
GABA-A receptor alpha-5/beta-3/gamma-2	Ion channel	P18507 P28472 P31644	GBRG2_HUMAN GBRB3_HUMAN GBRA5_HUMAN	POSITIVE ALLOSTERIC MODULATOR			WOMBAT-PK	CHEMBL

External reference:

ID	Source
D00694	KEGG_DRUG
5991-71-9	SECONDARY_CAS_RN
23887-31-2	SECONDARY_CAS_RN
2353	RXNORM
4018712	VANDF
4019688	VANDF
C0008174	UMLSCUI
CHEBI:59590	CHEBI
CHEMBL1213252	ChEMBL_ID
CHEMBL2106085	ChEMBL_ID
CHEMBL2096631	ChEMBL_ID
DB00628	DRUGBANK_ID
2809	PUBCHEM_CID
7548	IUPHAR_LIGAND_ID
MS63G8NQUI	UNII
388	MMSL
4481	MMSL
d00198	MMSL
001456	NDDF
001457	NDDF
001458	NDDF
371349001	SNOMEDCT_US
387453004	SNOMEDCT_US
39815009	SNOMEDCT_US
D003009	MESH_DESCRIPTOR_UI
2224	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Clorazepate Dipotassium	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0030	TABLET	3.75 mg	ORAL	ANDA	19 sections
Clorazepate Dipotassium	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0040	TABLET	7.50 mg	ORAL	ANDA	19 sections
Clorazepate Dipotassium	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0070	TABLET	15 mg	ORAL	ANDA	19 sections
CLORAZEPATE DIPOTASSIUM	Human Prescription Drug Label	1	13107-319	TABLET	3.75 mg	ORAL	ANDA	16 sections
CLORAZEPATE DIPOTASSIUM	Human Prescription Drug Label	1	13107-320	TABLET	7.50 mg	ORAL	ANDA	16 sections
CLORAZEPATE DIPOTASSIUM	Human Prescription Drug Label	1	13107-321	TABLET	15 mg	ORAL	ANDA	16 sections
Clorazepate Dipotassium	HUMAN PRESCRIPTION DRUG LABEL	1	21695-433	TABLET	3.75 mg	ORAL	ANDA	20 sections
Clorazepate Dipotassium	HUMAN PRESCRIPTION DRUG LABEL	1	21695-434	TABLET	7.50 mg	ORAL	ANDA	20 sections
Clorazepate Dipotassium	HUMAN PRESCRIPTION DRUG LABEL	1	43063-030	TABLET	15 mg	ORAL	ANDA	19 sections
Clorazepate Dipotassium	HUMAN PRESCRIPTION DRUG LABEL	1	43063-030	TABLET	15 mg	ORAL	ANDA	19 sections
Clorazepate Dipotassium	HUMAN PRESCRIPTION DRUG LABEL	1	43063-893	TABLET	15 mg	ORAL	ANDA	24 sections
Clorazepate Dipotassium	HUMAN PRESCRIPTION DRUG LABEL	1	51672-4042	TABLET	3.75 mg	ORAL	ANDA	24 sections
Clorazepate Dipotassium	HUMAN PRESCRIPTION DRUG LABEL	1	51672-4043	TABLET	7.50 mg	ORAL	ANDA	24 sections
Clorazepate Dipotassium	HUMAN PRESCRIPTION DRUG LABEL	1	51672-4044	TABLET	15 mg	ORAL	ANDA	24 sections
TranxeneT-Tab	HUMAN PRESCRIPTION DRUG LABEL	1	55292-302	TABLET	7.50 mg	ORAL	NDA	19 sections
TranxeneT-Tab	HUMAN PRESCRIPTION DRUG LABEL	1	55292-304	TABLET	7.50 mg	ORAL	NDA	19 sections
Clorazepate dipotassium	HUMAN PRESCRIPTION DRUG LABEL	1	63304-552	TABLET	3.75 mg	ORAL	ANDA	16 sections
Clorazepate dipotassium	HUMAN PRESCRIPTION DRUG LABEL	1	63304-553	TABLET	7.50 mg	ORAL	ANDA	16 sections
Clorazepate dipotassium	HUMAN PRESCRIPTION DRUG LABEL	1	63304-554	TABLET	15 mg	ORAL	ANDA	16 sections
Clorazepate dipotassium	HUMAN PRESCRIPTION DRUG LABEL	1	67046-904	TABLET	7.50 mg	ORAL	ANDA	16 sections
Clorazepate Dipotassium	HUMAN PRESCRIPTION DRUG LABEL	1	67046-906	TABLET	7.50 mg	ORAL	ANDA	20 sections
Clorazepate dipotassium	HUMAN PRESCRIPTION DRUG LABEL	1	67046-907	TABLET	15 mg	ORAL	ANDA	16 sections